On the other hand, the discovery and understanding of the function of proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme in lipid metabolism has led to the development of PCSK9 inhibitors to treat hypercholesterolemia and atherosclerotic cardiovascular disease. Here, PCSK9 is linked to familial hypercholesterolemia.